期刊文献+

CA4P脂质体的制备工艺研究 被引量:7

Preparation process of Combretastatin A4 Prodrug liposome
原文传递
导出
摘要 目的研究CA4P脂质体的处方及制备工艺。方法以包封率为主要评价指标考察制备方法;用透射电镜和粒径测定仪表征脂质体的形态和粒径;用HPLC法测定脂质体中CA4P的包封率和载药量;以正交设计筛选优化最佳处方工艺。结果脂质体的平均粒径为167nm,Zeta电位为-24.3mV,最佳工艺处方的药-脂比为1:12,磷脂-胆固醇为8:1,有机相-水相体积为4:1,水合介质为0.9%NaCl;制备3批脂质体的平均包封率为58%、载药量为4.8%。结论逆相蒸发-探头超声法可制备具有较高包封率的CA4P脂质体。 OBJECTIVE To study the formulation and preparation technique of Combretastin A4 prodrug (CA4P) liposome. METHODS Liposme was prepared with different methods, using entrapment efficiency as the optimized index. The shape and particle size were determined by electronic microscopy and Zetamaster, and the encapsulation efficiencies were determined by HPLC. The orthogonal design method was used to optimize the formulation and preparation technique of CA4P liposome. RESULTS The average size was about 167 nm and Zete -potential of -24.3 inV. The optimal preparation conditions of CA4P liposome were as follows:the proportion of CA4P and lipids in weight was 1 : 12, soybean phosphatidylcholine : cholesterol was 8 : 1, oil :water was 4 : 1, the hydration medium was 0.9% NaCl. The average encapsulation efficiency of the optimized liposome was 58.0% and the mean drug - loading efficiency was 4.8%. CONCLUSION The entrapment efficiency of CA4P liposome prepared with reverse evaporation method and probe ultrasonic technique is optimized.
出处 《华西药学杂志》 CAS CSCD 北大核心 2009年第6期594-596,共3页 West China Journal of Pharmaceutical Sciences
关键词 康普瑞丁磷酸二钠 脂质体 逆相蒸发-探头超声法 高效液相色谱法 Combretastatin A4 prodrug Liposome Reverse evaporation method and probe ultrasonic technique HPLC
  • 相关文献

参考文献5

  • 1尹华熙,吴萍,徐小平,田晨煦.抗肿瘤新药CA4P及其有关物质的IR结构解析[J].华西药学杂志,2008,23(5):523-525. 被引量:6
  • 2Malcontenti - Wilson C. Compretastatin A4 prodrug study of effect on the growth and the miscrovasculatue of colorectal liver metastases in amurine model [ J ]. Clin Cancer Res, 2001,7 : 1052 - 1060.
  • 3Nabha SM. Evaluation of compretastatin A4 prodrug in a non - Hodgkins lymphoma xenograft model [J]. Preclinical Efficac Drugs,2001,12:57 - 63.
  • 4Hill SA. Schudule dependence of compretastatin A4 phosphate in trans - planted and spontaneous models [ J ]. Int J Canc, 2002, 102:70 - 74.
  • 5陆榕 樊慧蓉 刘昌 等.风车子素A4磷酸盐的大鼠药动学研究.中草药,2006,37:147-149.

二级参考文献5

  • 1Pettit GR, Singh SB, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatinA4 [ J ]. Experientia, 1989,45 : 205 - 211.
  • 2Pettit GR, Temple C, Narayanan VL, et al. Antineoplastic agents 322. synthesis of combretastatin A -4 prodrugs[J]. Anticancer Drug Des, 1995,10 : 299 - 309.
  • 3Brooks AC, Nash GE, Parkins CS, et al. Combretastatin A - 4- phosphate (CA -4 -P) induces neutrophil recruitment to cultured endothelial cells under flow[J]. J Vase Res, in Press, 2001.
  • 4Dark GD, Hill SA, Prise VE, et al. Combretastatin A - 4, an agent that displays potent and selective toxicity toward tumor vasculature[ J]. Cancer Res, 1997,57 : 1829 - 1834.
  • 5George RP, Monte RR. Antineoplastic agents 389. new syntheses of the combretastatin A -4 Prodrug [ J ]. Anti - Cancer Drug Design ,1998, 13:183 - 191.

共引文献7

同被引文献61

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部